{"doi":"10.1111/ejh.70108","title":"Bridging With Chimeric Antigen Receptor T‐Cell Therapy or Chemotherapy to Allo‐\n                    <scp>HSCT</scp>\n                    in B‐\n                    <scp>ALL</scp>\n                    : A Comparison of Treatment Complications and Survival","abstract":"<jats:title>ABSTRACT</jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives</jats:title>\n                    <jats:p>Comparisons of safety and efficacy of Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) following complete remission (CR) achieved by Chimeric antigen receptor T (CAR‐T) cell therapy versus chemotherapy for B‐cell acute lymphoblastic leukemia (B‐ALL) have not been fully discussed.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>\n                      We performed a comparison of transplant outcomes in 443 consecutive B‐ALL patients who received allo‐HSCT after achieving CR with CAR‐T therapy (\n                      <jats:italic>n</jats:italic>\n                       = 50) or with chemotherapy (\n                      <jats:italic>n</jats:italic>\n                       = 393). The median follow‐up time was 30 months (range: 1–62 months).\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>\n                      The CAR‐T group had a lower incidence of chronic graft‐versus‐host disease (30.9% vs. 44.0%,\n                      <jats:italic>p</jats:italic>\n                       = 0.020). We also found that the incidence of veno‐occlusive disease was higher in the CAR‐T group compared to the chemotherapy group (4% vs. 0.5%;\n                      <jats:italic>p</jats:italic>\n                       = 0.003). The study revealed that both the CAR‐T and chemotherapy groups exhibited comparable overall survival (90.9% vs. 94.6%,\n                      <jats:italic>p</jats:italic>\n                       = 0.158) and relapse incidences (9.1% vs. 8.4%,\n                      <jats:italic>p</jats:italic>\n                       = 0.513). However, incidences of non‐relapse mortality after transplantation were higher in the CAR‐T group (10.9% vs. 4.3%,\n                      <jats:italic>p</jats:italic>\n                       = 0.016), and leukemia‐free survival was lower in the CAR‐T group compared to the chemotherapy group (80.0% vs. 86.8%,\n                      <jats:italic>p</jats:italic>\n                       = 0.040).\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions</jats:title>\n                    <jats:p>Our data indicate that, in B‐ALL patients, most treatment‐related complications and survival were comparable between CAR T‐cell therapy and chemotherapy followed by allo‐HSCT.</jats:p>\n                  </jats:sec>","journal":"European Journal of Haematology","year":2026,"id":601649,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":491582,"name":"Jun Kong","orcid":"0000-0001-8757-8339","position":1,"is_corresponding":false},{"id":1169071,"name":"Meng Lv","orcid":"0000-0001-6625-9523","position":2,"is_corresponding":false},{"id":1542737,"name":"Xiao‐Dong Mo","orcid":null,"position":3,"is_corresponding":false},{"id":1542738,"name":"Yu‐Qian Sun","orcid":null,"position":4,"is_corresponding":false},{"id":1542739,"name":"Yi‐Fei Cheng","orcid":null,"position":5,"is_corresponding":false},{"id":1542740,"name":"Lan‐Ping Xu","orcid":null,"position":6,"is_corresponding":false},{"id":1542741,"name":"Xiao‐Hui Zhang","orcid":null,"position":7,"is_corresponding":false},{"id":1542742,"name":"Xiao‐Jun Huang","orcid":null,"position":8,"is_corresponding":false},{"id":1431357,"name":"Yu Wang","orcid":"0000-0003-1253-7465","position":9,"is_corresponding":false},{"id":274425,"name":"Ning Wu","orcid":"0000-0001-7485-0436","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Bridging With Chimeric Antigen Receptor T‐Cell Therapy or Chemotherapy to Allo‐\n                    <scp>HSCT</scp>\n                    in B‐\n                    <scp>ALL</scp>\n                    : A Comparison of Treatment Complications and Survival","abstract":"<jats:title>ABSTRACT</jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives</jats:title>\n                    <jats:p>Comparisons of safety and efficacy of Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) following complete remission (CR) achieved by Chimeric antigen receptor T (CAR‐T) cell therapy versus chemotherapy for B‐cell acute lymphoblastic leukemia (B‐ALL) have not been fully discussed.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>\n                      We performed a comparison of transplant outcomes in 443 consecutive B‐ALL patients who received allo‐HSCT after achieving CR with CAR‐T therapy (\n                      <jats:italic>n</jats:italic>\n                       = 50) or with chemotherapy (\n                      <jats:italic>n</jats:italic>\n                       = 393). The median follow‐up time was 30 months (range: 1–62 months).\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>\n                      The CAR‐T group had a lower incidence of chronic graft‐versus‐host disease (30.9% vs. 44.0%,\n                      <jats:italic>p</jats:italic>\n                       = 0.020). We also found that the incidence of veno‐occlusive disease was higher in the CAR‐T group compared to the chemotherapy group (4% vs. 0.5%;\n                      <jats:italic>p</jats:italic>\n                       = 0.003). The study revealed that both the CAR‐T and chemotherapy groups exhibited comparable overall survival (90.9% vs. 94.6%,\n                      <jats:italic>p</jats:italic>\n                       = 0.158) and relapse incidences (9.1% vs. 8.4%,\n                      <jats:italic>p</jats:italic>\n                       = 0.513). However, incidences of non‐relapse mortality after transplantation were higher in the CAR‐T group (10.9% vs. 4.3%,\n                      <jats:italic>p</jats:italic>\n                       = 0.016), and leukemia‐free survival was lower in the CAR‐T group compared to the chemotherapy group (80.0% vs. 86.8%,\n                      <jats:italic>p</jats:italic>\n                       = 0.040).\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions</jats:title>\n                    <jats:p>Our data indicate that, in B‐ALL patients, most treatment‐related complications and survival were comparable between CAR T‐cell therapy and chemotherapy followed by allo‐HSCT.</jats:p>\n                  </jats:sec>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"41560408","pmcid":null,"openalex_id":"https://openalex.org/W7125200891","authors":[],"funders":[{"funder_name":"National Key Research and Development Program of China","grant_id":"2023YFC2508905","title":null},{"funder_name":"National Key Research and Development Program of China","grant_id":"2022YFA1103300","title":null},{"funder_name":"National Natural Science Foundation of China","grant_id":"82470214","title":null},{"funder_name":"National Natural Science Foundation of China","grant_id":"82270227","title":null},{"funder_name":"Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park","grant_id":"Z211100002921071","title":null},{"funder_name":"Major Program of the National Natural Science Foundation of China","grant_id":"82293630","title":null},{"funder_name":"Beijing Research Ward Excellence Program","grant_id":"BRWEP2024W134080102","title":null},{"funder_name":"Peking University Medicine Fund for world's leading discipline or discipline cluster development","grant_id":"71003Y3035","title":null}],"total_grants":8,"fwci":0.0,"citation_percentile":0.05577764,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":"http://doi.wiley.com/10.1002/tdm_license_1.1","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.70108","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/ejh.70108","host_type":"publisher"},{"url":"https://doi.org/10.1111/ejh.70108","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/41560408","host_type":"repository"}],"fields_of_study":["CAR-T cell therapy research","Acute Lymphoblastic Leukemia research","Chronic Myeloid Leukemia Treatments","Humans","Hematopoietic Stem Cell Transplantation","Female","Male","Adult","Adolescent","Transplantation, Homologous","Child","Middle Aged","Child, Preschool","Young Adult","Treatment Outcome","Immunotherapy, Adoptive","Graft vs Host Disease","Receptors, Chimeric Antigen","Precursor B-Cell Lymphoblastic Leukemia-Lymphoma","Bridge Therapy","Combined Modality Therapy","Remission Induction"],"mesh_terms":["Receptors, Chimeric Antigen","Bridge Therapy","Adolescent","Adult","Aged","Child","Child, Preschool","Combined Modality Therapy","Female","Graft vs Host Disease","Humans","Male","Middle Aged","Remission Induction","Transplantation, Homologous","Precursor B-Cell Lymphoblastic Leukemia-Lymphoma","Immunotherapy, Adoptive","Treatment Outcome","Hematopoietic Stem Cell Transplantation","Young Adult"],"keywords":["Chemotherapy","Chimeric antigen receptor","Bridging (networking)","Immunotherapy","Receptor","Antigen","Allogeneic hematopoietic stem cell transplantation","Outcomes","Chimeric Antigen Receptor T‐cell Therapy","Treatment‐related Complications","B‐cell Acute Lymphoblastic Leukemia"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T17:00:05.000319Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}